Risk Factors Update Summary
- Gross margin dependent on diversified demand mix to avoid negative impact on margin. This is crucial for maintaining balanced revenue growth and yield improvements.
- Completion of BLA submission for Avance Nerve Graft in the third quarter of 2024 is crucial.
- Revenue now derived from five products instead of four, with Avance Nerve Graft representing approximately 60%.
- Acquisition of Cook Biotech by RTI Surgical may impact relationship and Distribution Agreement.
- Failure to efficiently scale production could lead to shutdowns and impact operating margins.
- Distribution Agreement extended to December 31, 2030, potentially impacting operations positively.
- Transition to new accounts may disrupt customer receivables and vendor payments, affecting liquidity.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=805928&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.